This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care Winners & Losers: Alkermes

Updated from 3:40 p.m. ET

A J.P. Morgan analyst said Tuesday that health care is currently the most attractive sector in the market, and stocks in health care could make an average gain of 25% in 2009.

Thomas J. Lee upgraded the health care sector to Overweight from Neutral, saying the stocks are generally inexpensive compared with their expected earnings, and profit growth could exceed Wall Street expectations. Lee said pharmacy benefits managers, biotechnology companies and pharmaceutical companies are the most attractive areas of the industry.

Health care stocks are getting stronger but are not yet at their peak value, as consumer staple companies are, Lee wrote. He said shares of health care service companies are closer to a peak.

"Given the continued weak (economic) outlook, coupled with low visibility, health care is likely to continue outperforming," he said. The analyst also believes that health care is less vulnerable to economic weakness than many other industries.

Lee said there could be significant buyout activity in the sector in keeping with shareholder demand, and big drug companies may look to combine or buy smaller companies to fight off the revenue they will lose as patents on key products expire.

In just such a move, Eli Lilly (LLY - Get Report) bought cancer drug maker ImClone Systems for more than $6 billion in November, and some analysts are expecting similar deals to follow.

Lee said biotechnology stocks may make the largest gains, along with health care equipment and life science tools and services. He expects little stock movement from facility operators and suppliers.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALKS $37.59 -4.10%
ARAY $5.31 0.00%
CRL $79.02 0.28%
EBS $38.47 -2.00%
ETRM $0.73 -2.30%


Chart of I:DJI
DOW 17,700.88 -50.03 -0.28%
S&P 500 2,056.51 -6.86 -0.33%
NASDAQ 4,746.7140 -16.51 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs